
Cosmetic drugmaker Evolus' EOLS.O shares rise 1.6% to $14.58
Evolus reported late on Tuesday Q4 adjusted income of $6.7 million, on strong sales of its cosmetic injection, compared with a year-ago loss of $3.7 million
Expects 2025 revenue between $345 million and $355 million, compared with analysts' average expectation of $351.3 million, according to data compiled by LSEG
Company projects total net revenue of at least $700 million by 2028
Brokerage H.C. Wainwright & Co says company's tone regarding the demand in the aesthetics market was 'reassuring' given recent macro-economic uncertainty
In the last 12 months, EOLS has fallen 2.7%